

# Wrightington, Wigan and Leigh Teaching Hospitals

NHS Foundation Trust

Information Governance Department

Suite 9  
Buckingham Row  
Brick Kiln Lane  
Wigan  
WN1 1XX

Email: [foi@wwl.nhs.uk](mailto:foi@wwl.nhs.uk)  
Web: [www.wwl.nhs.uk](http://www.wwl.nhs.uk)

Ref: FOI/2024/9968

Date Received: 8<sup>th</sup> July 2024

Response Due: 5<sup>th</sup> August 2024

Date: 22<sup>nd</sup> July 2024

Dear Sir/Madam

With reference to your request for information received on 8<sup>th</sup> July 2024, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

**Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?**

8.

**Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?**

5.

**Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:**

- **R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**  
<5.
- **R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)**  
0.
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine)**  
0.
- **Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)**  
<5.
- **R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)**  
0.

- **R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)**  
0.
- **Axicabtagene ciloleucel (Yescarta)**  
0.
- **Tisagenlecleucel**  
0.
- **Epcoritamab**  
0.
- **Loncastuximab tesirine**  
0.
- **Glofitamab**  
0.
- **Any other SACT**  
0.
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**  
0.

**Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):**

- **Axicabtagene ciloleucel (Yescarta)**  
0.
- **Tisagenlecleucel**  
0.
- **Pola-BR (polatuzumab vedotin with rituximab and bendamustine)**  
0.
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**  
0.
- **Any other treatments**  
0.

**Q4. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:**

- **CAR-T Therapy (E.g. Axicabtagene ciloleucel)**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **Any other treatment**

The Trust is unable to provide this data as it is not recorded centrally, if recorded it would be held within individual case notes. As case notes are for the care and treatment of patients, we do not request staff to interrogate them in order to collate the information required to respond to Freedom of Information requests.

**Q5. Do you participate in any active clinical trials for Diffuse Large B-Cell Lymphoma (DLBCL)? If so, can you please provide the name of each trial along with the number of patients taking part or enrolling?**

No.

The Trust has a policy of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- a) Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and
- b) Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,



Hazel Hendriksen  
Director of Operations and Performance

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire, SK9 5AF

Helpline number: 0303 123 111